Companies/Knight Therapeutics Inc.

Company profile

Knight Therapeutics Inc.

OTC: KHTRF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Montreal, QCReports USD

#239 of 1,394 Healthcare companies by revenue65th-percentile growth

EA Score

77B+

FH 79DQ —GM 71SS 73

v0.1 · 45/100 weight · provisional

↑ Piotroski F, growth stability · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$369.8M

Rev growth YoY (TTM)

+37.9%

Net income (FY)

-$3.8M

Employees

745

Market cap

$678.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$321.7M449.7M CAD2025

Net income-$3.8M-5.4M CAD2025

Operating income-$1.6M-2.2M CAD2025

Total assets$762.8M1.0B CAD2025

Liabilities$203.4M278.8M CAD2025

Equity$559.4M766.6M CAD2025

Revenue trend

FY2018 – FY2025 · USD

$9.6M

FY18

$35.8M

FY19

$148.8M

FY20

$194.2M

FY21

$225.6M

FY22

$243.2M

FY23

$271.1M

FY24

$321.7M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Knight Therapeutics Inc. booked $321.7M in FY2025 revenue, growing 19% year over year — faster than most Healthcare companies we track, at a -1.2% net margin.

Peers · Healthcare

Ginkgo Bioworks Holdings, Inc.44D 4D Molecular Therapeutics, Inc.58C Phreesia, Inc.68B ProKidney Corp.41D

Key facts

CEOSamira Sakhia

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersMontreal, QC

ExchangeOTC: KHTRF

Employees745

IPO date2014-04-03

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.